Merck & Company (MRK) Q2 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.13

Estimate

-$0.26

Surprise

+49.4%

Score at report (before → after)

5.9 → 5.7/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Merck & Company (MRK) reported a narrower loss than forecast — adjusted EPS of -$0.13 against the -$0.26 estimate (a 49.4% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Buy (Wait) (5.9/10) to Sell at 5.7/10 after the report — the engine's score fell despite the beat.

TrendMatrix currently rates MRK Sell at 5.0/10.

4 of the last 4 quarters beat the estimate; this quarter's +49.4% surprise compares with a +18.5% four-quarter average. Next scheduled report: 2026-10-29.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$148.08

Price target

$151.19

Stop

$141.62

Upside to target

+2.1%

Model outputs from TrendMatrix’s engine as of 2026-09-24 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Drug Manufacturers - General

Market cap

$372.32B

P/E (fwd)

15.8

P/E (ttm)

118.8

52-week range

$77.58–$156.92

Off 52-week high

5.6%

RSI (14)

44

Volume vs avg

0.99×

Score today

5.0/10